Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling

Anamaria Balic, Morten Drbæy Sørensen, Sara Maria Trabulo, Bruno Sainz, Michele Cioffi, Catarina R. Vieira, Irene Miranda-Lorenzo, Manuel Hidalgo, Joerg Kleeff, Mert Erkan, Christopher Heeschen

Research output: Contribution to journalArticle

Abstract

Pancreaticductal adenocarcinoma is one of the deadliest carcinomas and is characterized by highly tumorigenic and metastatic cancer stem cells (CSC). CSCs evade available therapies, which preferentially target highly proliferative and more differentiated progenies, leaving behind CSCs as a putative source for disease relapse. Thus, to identify potentially more effective treatment regimens, we screened established and new compounds for their ability to eliminate CSCs in primary pancreatic cancer (stem) cells in vitro and corresponding patient-derived pancreatic cancer tissue xenografts in vivo. Intriguingly, we found that in vitro treatment with the antimalarial agent chloroquine significantly decreased CSCs, translating into diminished in vivo tumorigenicity and invasiveness in a large panel of pancreatic cancers. In vivo treatment in combinationwith gemcitabine was capable of more effectively eliminating established tumors and improved overall survival. The inhibitory effect of chloroquine was not related to inhibition of autophagy, but was due to inhibition of CXCL12/CXCR4 signaling, resulting in reduced phosphorylation of ERK and STAT3. Furthermore, chloroquine showed potent inhibition of hedgehog signaling by decreasing the production of Smoothened, translating into a significant reduction in sonic hedgehog-induced chemotaxis and downregulation of downstream targets in CSCs and the surrounding stroma. Our study demonstrates that via to date unreported effects, chloroquine is an effective adjuvant therapy to chemotherapy, offering more efficient tumor elimination and improved cure rates. Chloroquine should be further explored in the clinical setting as its success may help to more rapidly improve the poor prognosis of patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)1758-1771
Number of pages14
JournalMolecular Cancer Therapeutics
Volume13
Issue number7
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Chloroquine
Pancreatic Neoplasms
gemcitabine
Therapeutics
Aptitude
Autophagy
Antimalarials
Chemotaxis
Heterografts
Neoplasms
Adenocarcinoma
Down-Regulation
Phosphorylation
Inhibition (Psychology)
Carcinoma
Recurrence
Drug Therapy
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Balic, A., Sørensen, M. D., Trabulo, S. M., Sainz, B., Cioffi, M., Vieira, C. R., ... Heeschen, C. (2014). Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Molecular Cancer Therapeutics, 13(7), 1758-1771. https://doi.org/10.1158/1535-7163.MCT-13-0948

Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. / Balic, Anamaria; Sørensen, Morten Drbæy; Trabulo, Sara Maria; Sainz, Bruno; Cioffi, Michele; Vieira, Catarina R.; Miranda-Lorenzo, Irene; Hidalgo, Manuel; Kleeff, Joerg; Erkan, Mert; Heeschen, Christopher.

In: Molecular Cancer Therapeutics, Vol. 13, No. 7, 2014, p. 1758-1771.

Research output: Contribution to journalArticle

Balic, A, Sørensen, MD, Trabulo, SM, Sainz, B, Cioffi, M, Vieira, CR, Miranda-Lorenzo, I, Hidalgo, M, Kleeff, J, Erkan, M & Heeschen, C 2014, 'Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling', Molecular Cancer Therapeutics, vol. 13, no. 7, pp. 1758-1771. https://doi.org/10.1158/1535-7163.MCT-13-0948
Balic, Anamaria ; Sørensen, Morten Drbæy ; Trabulo, Sara Maria ; Sainz, Bruno ; Cioffi, Michele ; Vieira, Catarina R. ; Miranda-Lorenzo, Irene ; Hidalgo, Manuel ; Kleeff, Joerg ; Erkan, Mert ; Heeschen, Christopher. / Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. In: Molecular Cancer Therapeutics. 2014 ; Vol. 13, No. 7. pp. 1758-1771.
@article{4c9e08f9cb444fd88d3becbb5780bed2,
title = "Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling",
abstract = "Pancreaticductal adenocarcinoma is one of the deadliest carcinomas and is characterized by highly tumorigenic and metastatic cancer stem cells (CSC). CSCs evade available therapies, which preferentially target highly proliferative and more differentiated progenies, leaving behind CSCs as a putative source for disease relapse. Thus, to identify potentially more effective treatment regimens, we screened established and new compounds for their ability to eliminate CSCs in primary pancreatic cancer (stem) cells in vitro and corresponding patient-derived pancreatic cancer tissue xenografts in vivo. Intriguingly, we found that in vitro treatment with the antimalarial agent chloroquine significantly decreased CSCs, translating into diminished in vivo tumorigenicity and invasiveness in a large panel of pancreatic cancers. In vivo treatment in combinationwith gemcitabine was capable of more effectively eliminating established tumors and improved overall survival. The inhibitory effect of chloroquine was not related to inhibition of autophagy, but was due to inhibition of CXCL12/CXCR4 signaling, resulting in reduced phosphorylation of ERK and STAT3. Furthermore, chloroquine showed potent inhibition of hedgehog signaling by decreasing the production of Smoothened, translating into a significant reduction in sonic hedgehog-induced chemotaxis and downregulation of downstream targets in CSCs and the surrounding stroma. Our study demonstrates that via to date unreported effects, chloroquine is an effective adjuvant therapy to chemotherapy, offering more efficient tumor elimination and improved cure rates. Chloroquine should be further explored in the clinical setting as its success may help to more rapidly improve the poor prognosis of patients with pancreatic cancer.",
author = "Anamaria Balic and S{\o}rensen, {Morten Drb{\ae}y} and Trabulo, {Sara Maria} and Bruno Sainz and Michele Cioffi and Vieira, {Catarina R.} and Irene Miranda-Lorenzo and Manuel Hidalgo and Joerg Kleeff and Mert Erkan and Christopher Heeschen",
year = "2014",
doi = "10.1158/1535-7163.MCT-13-0948",
language = "English (US)",
volume = "13",
pages = "1758--1771",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling

AU - Balic, Anamaria

AU - Sørensen, Morten Drbæy

AU - Trabulo, Sara Maria

AU - Sainz, Bruno

AU - Cioffi, Michele

AU - Vieira, Catarina R.

AU - Miranda-Lorenzo, Irene

AU - Hidalgo, Manuel

AU - Kleeff, Joerg

AU - Erkan, Mert

AU - Heeschen, Christopher

PY - 2014

Y1 - 2014

N2 - Pancreaticductal adenocarcinoma is one of the deadliest carcinomas and is characterized by highly tumorigenic and metastatic cancer stem cells (CSC). CSCs evade available therapies, which preferentially target highly proliferative and more differentiated progenies, leaving behind CSCs as a putative source for disease relapse. Thus, to identify potentially more effective treatment regimens, we screened established and new compounds for their ability to eliminate CSCs in primary pancreatic cancer (stem) cells in vitro and corresponding patient-derived pancreatic cancer tissue xenografts in vivo. Intriguingly, we found that in vitro treatment with the antimalarial agent chloroquine significantly decreased CSCs, translating into diminished in vivo tumorigenicity and invasiveness in a large panel of pancreatic cancers. In vivo treatment in combinationwith gemcitabine was capable of more effectively eliminating established tumors and improved overall survival. The inhibitory effect of chloroquine was not related to inhibition of autophagy, but was due to inhibition of CXCL12/CXCR4 signaling, resulting in reduced phosphorylation of ERK and STAT3. Furthermore, chloroquine showed potent inhibition of hedgehog signaling by decreasing the production of Smoothened, translating into a significant reduction in sonic hedgehog-induced chemotaxis and downregulation of downstream targets in CSCs and the surrounding stroma. Our study demonstrates that via to date unreported effects, chloroquine is an effective adjuvant therapy to chemotherapy, offering more efficient tumor elimination and improved cure rates. Chloroquine should be further explored in the clinical setting as its success may help to more rapidly improve the poor prognosis of patients with pancreatic cancer.

AB - Pancreaticductal adenocarcinoma is one of the deadliest carcinomas and is characterized by highly tumorigenic and metastatic cancer stem cells (CSC). CSCs evade available therapies, which preferentially target highly proliferative and more differentiated progenies, leaving behind CSCs as a putative source for disease relapse. Thus, to identify potentially more effective treatment regimens, we screened established and new compounds for their ability to eliminate CSCs in primary pancreatic cancer (stem) cells in vitro and corresponding patient-derived pancreatic cancer tissue xenografts in vivo. Intriguingly, we found that in vitro treatment with the antimalarial agent chloroquine significantly decreased CSCs, translating into diminished in vivo tumorigenicity and invasiveness in a large panel of pancreatic cancers. In vivo treatment in combinationwith gemcitabine was capable of more effectively eliminating established tumors and improved overall survival. The inhibitory effect of chloroquine was not related to inhibition of autophagy, but was due to inhibition of CXCL12/CXCR4 signaling, resulting in reduced phosphorylation of ERK and STAT3. Furthermore, chloroquine showed potent inhibition of hedgehog signaling by decreasing the production of Smoothened, translating into a significant reduction in sonic hedgehog-induced chemotaxis and downregulation of downstream targets in CSCs and the surrounding stroma. Our study demonstrates that via to date unreported effects, chloroquine is an effective adjuvant therapy to chemotherapy, offering more efficient tumor elimination and improved cure rates. Chloroquine should be further explored in the clinical setting as its success may help to more rapidly improve the poor prognosis of patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84904168687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904168687&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-13-0948

DO - 10.1158/1535-7163.MCT-13-0948

M3 - Article

VL - 13

SP - 1758

EP - 1771

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -